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antonia.ertelt@fu-berlin.deAbstractThis review summarizes similarities and differences between the metabolic syndromes
in humans and equines, concerning the anatomy, symptoms, and pathophysiological
mechanisms. In particular, it discusses the structure and distribution of adipose tissue and its
specific metabolic pathways. Furthermore, this article provides insights and focuses on issues







(2014) 3, R81–R93IntroductionMetabolic syndrome in humans was first described almost
50 years ago by Camus (1), but there was little interest in
this disease until the late 1980s, when it gained new
attention as ‘syndrome X’ or ‘the deadly quartet’ (2, 3).
According to the Adult Treatment Panel III of
the National Cholesterol Education Program (NCEP) and
the American Heart Association/National Heart, Lung
and Blood Institute (http://www.nhlbi.nih.gov/health/
health-topics/topics/ms/), three of the five criteria –
waist circumference, hypertension, elevated glucose levels
in the fasting state, elevated triglycerides, and decreased
HDL cholesterol – have to be met to establish the diagnosis
of human metabolic syndrome (HMS) (4).
A similar disease in horses, called ‘equine metabolic
syndrome’ (EMS), was first described by Johnson et al. (5)
and commonly accepted by a consensus committee and
the veterinary public. Although equine disease resembles
what we know from humans in many aspects, distinct
differences have been defined concerning the vascularstructures affected by the disease, typically the coronary
vessels in humans, while horses present with an increased
risk of laminitis (6).
As pituitary pars intermedia dysfunction (PPID,
equine Cushing’s syndrome), EMS is a common endo-
crinologic disease with severe metabolic consequences in
equine medicine, and tends to affect young horses. EMS is
a very complex disorder that has been the focus of many
prior studies, as is HMS in human medicine (7).
In this paper, we aimed to review similarities and
differences between EMS and HMS, as this may allow
transfer of knowledge between both species.Anatomy and physiology of adipose tissue
Adipose or fat tissue, a special form of reticular connective
tissue, consists mainly of adipocytes. White and brown
adipose tissues in both horses and humans must be
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droplets. In addition to serving as fat storage, adipose
tissue has endocrine functions (8, 9, 10).
When weight is gained physiologically, the number of
fat cells does not change, but more lipids are stored in fat
cells, thereby causing an increase in cell size. By contrast,
obesity is characterized not only by hypertrophic expan-
sion of adipocytes, but also by a proliferation process
which increases the number of adipocytes (10).
There are two different types of adipocytes within
white adipose tissue: normal ‘white’ fat cells and ‘brite’
brown-in-white adipocytes. The latter express decoupled
protein 1, a classic marker of brown fat cells, although they
do not have the same molecular properties as brown fat
cells (11). The distribution of these ‘brite’ adipocytes
within white fat depots differed in mice (12). The different
distribution of these ‘brite’ adipocytes in fat depots affects
their metabolic processes, which could influence lipid
release in adipose tissue (12). However, the authors do not
mention any link with metabolic syndrome, and further
investigations are necessary to evaluate a relationship
between these ‘brite’ adipocytes and metabolic syndrome.
To date, there is a lack of studies in horses and humans
concerning this issue.
In addition to mature adipocytes, fat tissue contains
a so-called stromal vascular fraction, which is located
in loose connective tissue between fat cells and includes
macrophages, fibroblasts, pericytes, mast cells, micro-
vascular endothelial cells, and progenitor cells of the
adipogenic line. Fat cells or mature adipocytes are of
mesenchymal origin. The adipose tissue also constitutes a
reservoir of mesenchymal stem cells, which may serve as
an alternative cell source to bone marrow for tissue
engineering in humans and equids (13, 14). White fat
adipocytes are characterized by a single large fat droplet,
which forces the nucleus to be squeezed into a thin rim
at the periphery and a narrow hemline on the peripheral
cytoplasm. The polygonal cells have a diameter of up to
120 mm and are embedded in a network of reticular
fibers (collagen fibers of type III). White adipose tissue in
humans is macroscopically divided by connective tissue
septa into individual fat lobules, which are morpho-
logically, functionally, and angiologically independent
units. The areas of terminal circulation include an artery,
which is usually situated in the axis of the lobule, while
a paired vein collects blood on the surface. In contrast
to former reports, the fat tissue is a highly perfused tissue
(15, 16). Based on the cytoplasm area of fat cells, the
capillary bed reaches a high level in a similar density to
skeletal muscle. High vascularization of adipose tissue ishttp://www.endocrineconnections.org
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Published by Bioscientifica Ltdimportant for the exchange of metabolites, high meta-
bolic activity of individual fat cells, and its vital endocrine
function (16). To the best of our knowledge, there is a lack
of literature regarding whether and to what extent the
horse differs in histology compared with humans.
The amount of fat tissue in the bodyweight of a
normal adult human male is w8–20 and 21–33% in an
adult female (17). Human fat is oily in consistency,
semiliquid, and deep yellow at body temperature. The
consistency of the fat depends on the melting point of
fatty acids found in the fat tissue. A large proportion
of fatty acid in adipose tissue in humans is oleic acid, a
monounsaturated fatty acid that is assigned to omega 9
fatty acids based on the location of their double bond.
The amount of fat tissue in the bodyweight of a
normal-weight horse is 5% (18). There are currently no
studies focusing on differences in the amount of fat
tissue in bodyweight according to breed, gender, or age.
The white adipose tissue of the horse is also yellow and has
an oily consistency. The yellow color is due to an increased
incorporation of exogenous fat-soluble pigments, such as
carotenoids (8). The most abundant fatty acid in the
adipose tissue of the horse is also oleic acid (19).
In conclusion, the functional and structural condition
of fat cells in horses and humans is widely comparable;
therefore, a transfer of scientific knowledge from
humans to equids might be possible. However, the per-
centage amount of body fat differs, which could lead
to different amounts of metabolic products influencing
the body system.
Horses with EMS present with a characteristic fat
distribution showing deposits such as a cresty neck and at
the comb, side of the chest, hip region, and tail head. Large
omental fat deposits are also present, but not visible (Fig. 1).
Abdominal obesity is very common in humans,
particularly males, suffering from HMS. Predominant fat
accumulation in the femoral–gluteal region, commonly
seen in females, is associated with a lower risk of metabolic
disease (20, 21, 22).
The intra-abdominal fat accumulation in humans
amounts to 10% of bodyweight and includes omental,
mesenteric, and perirenal fat. Visceral fat surrounds
internal organs (viscera) and is often used as a synonym
for intra-abdominal fat (23). According to the definition of
HMS corresponding to the International Diabetes Federa-
tion (IDF), the waist circumference has to be measured at
R80 cm in women and R94 cm in men (http://www.idf.
org, 09/08/2011). Mesenteric and omental fat is of greater
importance in the development of insulin resistance,
because their fatty acids and adipokines pass through theThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Figure 1
Horse suffering from EMS and laminitis. The horse shows distribution of fat at characteristic sites. The rear limbs are positioned forward to relieve stress from
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more pronounced proinflammatory state than fat in other
locations (24, 25). However, there are other important
issues besides fat distribution which might influence the
development of HMS. Humans with a reduced energy
storage capacity in peripheral subcutaneous adipose
tissue, for example, show a higher fat content in the
liver, and skeletal and heart muscles. Consequently, they
are predisposed to insulin resistance and developing
type 2 diabetes mellitus (T2DM), an aspect that has to be
investigated in horses (17).
Furthermore, a higher basal lipolysis has been detected
in human adipocytes of omental and mesenteric adipose
tissues, compared with adipocytes of subcutaneous fat
tissue (26, 27, 28). The catecholamines stimulate lipolysis of
omental fat tissue to a higher degree than in subcutaneous
tissue, while insulin has a stronger inhibitory effect on
subcutaneous adipose tissue (24, 27). These differences are
partly due to the predominance of stimulating b-receptors
over antilipolytic a-adrenoreceptors, and lower insulinhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0038
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Published by Bioscientifica Ltdreceptor affinity of mesenteric omental adipocytes respect-
ively (27, 29). In addition to differences in lipolysis at
different localizations of adipose tissue, lipogenesis differs
at various fat depots (30, 31, 32). There are also differences
in gene expression in visceral and subcutaneous fat in
humans; however, isolated and cultured human preadipo-
cytes are still capable of their full and unique pattern of
gene expression, regardless of their environment (33, 34,
35, 36). Further research is required, particularly in equines,
to evaluate the importance of the site of fat deposition
and differences in metabolism of these fat depots to assess
their role in the development of metabolic syndrome.
Human adipose tissue produces adipokines, such as
leptin, resistin, adiponectin, and visfatin. Furthermore,
it releases inflammatory mediators, such as monocyte
chemotactic protein 1 (MCP1 (CCL2)) and plasminogen
activator inhibitor (PAI1 (SERPINE1)), as well as pro-
inflammatory cytokines, such as tumor necrosis factor
alpha (TNFa (TNF)), interleukin 1 (IL1 (IL1A)), IL6, and
IL8 (CXCL8) (37, 38). Differences in the production ofThis work is licensed under a Creative Commons
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4–13 3 :R84inflammatory mediators and their amount of expression
in various fat tissues have also been reported. Adipose
tissue around the nuchal ligament in horses is of particular
importance in the production of inflammatory mediators,
specifically IL1b and IL6. Furthermore, omental fat and
fat in muscles are suspected of playing an important
role in the development of a proinflammatory state,
because expression of TNF is increased and suppression
of cytokine signaling 3 (SOCS3) and Toll-like receptor 4
(TLR4) is significantly higher in comparison to subcu-
taneous fat in the area of the nuchal ligament (39, 40).
The gene expression of IL1, IL6, and TNFawas lower or
not different in obese, hyperinsulinemic horses compared
with euinsulinemic horses of normal weight (41). More-
over, no significant differences in gene expression of
TNFa, IL1b (IL1B), IL6, PAI1, or MCP1 mRNA were
recognized in different fat depots in horses affected by
EMS in comparison to healthy individuals (39). This is
surprising, as an increase in ILs was assumed to be a
causative factor in the pathogenesis of disease in previous
reports (9, 42). However, a positive correlation of TNF
expression, IL1 mRNA, and body condition score (BCS)
of horses was demonstrated in another study, in which
an increased cytokine expression seemed to be a risk factor
for the development of insulin resistance (9).
The importance of various inflammatory mediators
and their patterns of expression in the horse have been
controversially discussed. Marked differences seem to exist
between humans and equines. Further studies are required
to evaluate the reasons for these differences, as they may
be a key factor in the pathogenesis of equine disease.Clinical signs
Metabolic syndrome affects all organ systems involved in
metabolism to various degrees, and therefore, the disease
results in an impaired energy metabolism of the entire
organism (43).
Metabolic syndrome in humans is characterized by
abdominal obesity, hypertension, dyslipidemia (hypertri-
glyceridemia, decreased HDL, and cholesterolemia), insulin
resistance, increased oxidative burst, vascular dysfunction,
increased coagulability (increased fibrinogen and tissue
PAI1), and inflammation of adipose tissue (44, 45, 46, 47,
48, 49, 50, 51). All these factors contribute to a generalized
proinflammatory state of the organism.
Symptoms of metabolic syndrome are used to identify
humans with an increased risk of cardiovascular disease
(52). Owing to endothelial dysfunction, affected individ-
uals have an increased risk of developing atherosclerosis,http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0038
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Published by Bioscientifica Ltdcoronary flow reserve is impaired, and there are indepen-
dent associations among impaired coronary flow reserve,
increased stiffness of the aorta, systolic blood pressure,
and waist circumference (53, 54, 55). Symptoms of
atherosclerosis are found in the entire body, including
small vessels in the brain, extracranial carotid arteries,
and coronary vessels. Possible consequences of athero-
sclerosis are ischemia, thrombosis, angina pectoris, heart
attack, stroke, or sudden cardiac death (56).
Clinical signs in the horse include general (BCSR7/9;
57) or regional adiposity (cresty neck scoreR3/5), insulin
resistance, a predisposition to laminitis, and enhanced
oxidative burst (58, 59).
Laminitis, one of the most dangerous conditions in
horses, ponies, and donkeys, might be the counterpart to
central vascular dysfunction observed in humans. Severe
or recurrent laminitis may limit the performance of the
horse and may even result in euthanasia. Inflammation
and ischemia of the digital dermal tissue lead to
destruction of the interlaminar bond, which is the only
support of the distal phalanx within the hoof capsule,
and lameness, pedal bone rotation, and founder line for-
mation follows (Figs 2 and 3) (7, 60). Further signs
include hypertension, dyslipidemia, vascular dysfunction,
and increased coagulation (58, 61, 62, 63, 64, 65).
Another consequence of HMS is non-alcoholic fatty
liver disease. Pathological changes range from simple fatty
infiltration to advanced non-alcoholic steatohepatitis and
liver fibrosis (66, 67, 68). Studies on horses have not been
carried out thus far, but elevated liver enzyme levels are
occasionally found in affected horses, in particular g-GT,
corresponding to hepatic lipidosis detected in biopsy and
necropsy specimens (7, 64).
A carcinogenic effect is also associated with metabolic
syndrome in humans. It is assumed that females suffering
from HMS have an increased risk of developing breast
cancer (69). A predisposition to colon and rectal carci-
noma is also discussed (70). In addition, a twofold risk
of developing Barrett esophagus, a metaplastic transfor-
mation of the esophagus epithelium, has been reported
(51). Horses suffering from EMS are suspected of deve-
loping intestinal lipoma at a younger age, but further
investigation is warranted to confirm this hypothesis (71).
HMS is also associated with a higher prevalence of
rheumatoid arthritis compared with the general popu-
lation (72). Data in equines are missing.
Obese pregnant women have an increased risk of a
variety of gestational and perinatal problems, such as
gestational diabetes, fetal macrosomia, prematurity, birth
defects, pre-eclampsia, eclampsia, increased caesareanThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Figure 2
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5–13 3 :R85section rate, and stillbirth (73, 74). A prolonged estrous
cycle is observed in obese mares (9).
T2DM is of particular concern in humans suffering
from metabolic syndrome, and it may also develop in
horses in pronounced cases of EMS. At the time of diabetes
diagnosis, insulin resistance and relative insulin deficiency
may be present. Type 2 is the most common type of DM in
humans, accounting for about 90% of cases (http://www.
dft.org//types-diabetes). T2DM in horses may be more
common than generally considered and is the main
diabetes type observed in horses as well. Moreover,
T2DM is the end stage of EMS (71, 75).
Several risk factors have been associated with T2DM
and include a family history of diabetes, overweight,
dietary factors, physical inactivity, increasing age, high
blood pressure, ethnicity, impaired glucose tolerance,
history of gestational diabetes, and poor nutrition during
pregnancy (http://www.dft.org//types-diabetes).
Various international research centers have been
involved in identifying genes predisposed to T2DM in
humans. An association of T2DM with the calpain 10
(CAPN10) gene was initially identified, and later, its
association with the transcription factor 7-like 2http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0038
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Published by Bioscientifica Ltd(TCF7L2) gene, whose genetic variants in affected indi-
viduals increase the risk of diabetes byw1.5 times (76, 77).
The most common risk factors in horses include
metabolic syndrome and PPID. Unfortunately, studies on
equine medicine are lacking concerning genetic issue or
other predisposing factors compared with human medicine.
In summary, a significant clinical overlap exists
between both species. The most interesting question
seems to be whether a comparable genesis exists for
cardiovascular disease in humans and laminitis in equines.Pathophysiology of metabolic syndrome
Multiple hypotheses regarding the pathogenesis of meta-
bolic syndrome exist in human and equine medicine.
Some of them can be supported by evidence, while others
require further research.
One of these hypotheses regarding the development
of metabolic syndrome is the regulation of bodyweight
through the ponderostat. The ponderostat is a control or
supervisory point within the brain, probably located in
the hypothalamus, responsible for the regulation of body-
weight. Based on the regulation theory of cybernetics (78),This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Figure 3
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of the organism with the set point and responds to
weight loss with physical signals, such as hunger. The
mechanisms of the ponderostat are still poorly under-
stood, but probably do not depend directly on energy
supply. The regulation represents a very complex process,
which is influenced partly by the immune system (79).
The hormones leptin and oleoyl-estrone were postulated
as ponderostat signals. As the secretion capacity of leptin
differs within different fat depots depending on the age,
gender, and circadian rhythm, the likelihood that leptin
represents a true ponderostat signal is low (79, 80, 81, 82).
Recent studies have demonstrated that oleoyl-estrone
itself cannot be responsible for the control of body fat,
but a derivate might (83). In other words, the brain is
involved in the pathogenesis of metabolic syndrome, but
the exact mechanisms remain obscure.
White adipose tissue plays a key role in the develop-
ment of metabolic syndrome. Owing to an excessive
supply of energy, adipocytes increase in size causing
‘stress’ in adipose tissue. During expansion of hyper-
trophic adipocytes, a signaling cascade is initiated, leading
to the remodeling of tissue and recruitment of inflam-
matory cells. Owing to proinflammatory signals in adiposehttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0038
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Published by Bioscientifica Ltdtissue, there is an increased activity of macrophages,
which leads to further inflammation of adipose tissue.
Persistent inflammation leads to accelerated lipolysis and
an increased amount of free fatty acids in the bloodstream
(84). Inflammation of adipose tissue induces production
of proinflammatory adipokines that increase their own
synthesis and synthesis of other systemic inflammatory
markers and vice versa. Consequently, secondary synthesis
of acute-phase proteins in the liver is induced (37). The
result is the development of an inflammatory condition
that becomes chronic, as causative excessive obesity
cannot be eliminated by the immune system (43). This
chronic disease does not follow a classic pattern and leads
to a variety of pathological events that have still not been
investigated in detail.
One of the major pathological events of metabolic
syndrome in both species is insulin resistance. On the
one hand, this is caused by inhibition of insulin signal
transmission pathways by adipokines and cytokines and,
on the other hand, by accumulation of intracellular fat
in insulin-sensitive tissue, such as skeletal muscle, liver,
and pancreas (85, 86).
Oxidative stress is also involved in the development
of insulin resistance. Highly reactive toxic oxygen andThis work is licensed under a Creative Commons

















Review A Ertelt et al. Metabolic syndromes in humans
and equines
7–13 3 :R87nitric oxide (NO) radicals, which occur frequently in
mitochondrial weakness, induce cytocidal changes to
receptor proteins influencing their functions (87).
Holbrook et al. (41) found significant increases in
neutrophil oxidative stress in obese horses with
hyperinsulinemia. One receptor protein that might be
damaged through oxidative burst is glucose transporter 4
(GLUT4 (SLC2A4)). This receptor is one of the insulin-
dependent GLUTs responsible for the uptake of glucose
into cells and is significantly less expressed on the cell
surface of muscle and adipose tissue of insulin-resistant
horses (88).
The insulin receptor substrate 1 (IRS1), a substrate of
insulin receptor tyrosine kinase, gained increased interest
in human medicine as it plays a central role in the insulin-
stimulated signal transduction pathway (89, 90, 91, 92,
93, 94). However, Waller et al. (40) found no difference
in total content or serine phosphorylated IRS1 sampled
from visceral and subcutaneous adipose tissue and
skeletal muscle biopsies in horses with insulin resistance
compared with healthy subjects.
It is known that insulin resistance in muscle and
adipose tissue in humans leads to flooding of the liver
with free fatty acids, causing an increased triglyceride and
very-LDL synthesis in hepatocytes (95). The result is fatty
degeneration of the liver, increased synthesis of C-reactive
protein, fibrinogen, coagulation factors, and angiotensi-
nogen. The liver plays a major role in HMS regarding
the development of coagulation disorders, thrombosis,
vascular occlusion, and inflammation (96, 97).
Not only do free fatty acids lead to fatty liver
degeneration, but there is also a correlation with disturb-
ance in the intestinal microflora in HMS. Owing to
bacterial overgrowth and increased permeability of the
intestine, a greater amount of endotoxins and bacterial
DNA is transported to the liver via the portal vein. Once
they reach the liver, inflammation is induced due to
activation of the TLR (especially TLR4 and TLR9), a
receptor of the innate immune system, which potentiates
expression and secretion of proinflammatory cytokines.
This leads to the development of fatty liver degeneration
and, in turn, as well as in addition, this may induce insulin
resistance in insulin-sensitive tissues (98, 99, 100).
It is assumed that there is a correlation between TLR4
and downregulation of insulin response via SOCS3.
Cytokine signaling 3 is able to inhibit insulin signaling
pathways through leptin signaling in the hypothalamus,
as well as to inhibit insulin signaling pathways in the
adipose tissue and liver, which lead indirectly to insulin
resistance of peripheral organs (40).http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0038
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Published by Bioscientifica LtdAdditionally, an increased expression of the SOCS
may be caused by proinflammatory cytokines (101, 102).
An increase in SOCS3 protein in rodents leads to impaired
insulin response in the liver, adipose tissue, and skeletal
muscle (89, 103, 104). Whether this occurs in horses and
humans also requires further research.
A vicious circle exists in humans due to magnesium
deficiency, which may create an increasing excretion of
magnesium through the kidney induced by hyperglycemia
and hyperinsulinemia.This leads through differentpathways
to hypertension, glucose intolerance, and hyperlipidemia,
which additionally increases clearance of the electrolyte in
the kidney (105, 106). It remains to be elucidated whether
a magnesium deficiency in EMS exists and if there is an
association with laminitis. Magnesium deficiency may lead
to changes in the intracellular Ca2C/Mg2C ratio, which
induces an increase in vascular tone and increased secretion
of catecholamines through sympathetic nerve endings, and
this may ultimately lead to hypoperfusion in the vascular
bed of the hoof (105, 106, 107).
The most important and life-threatening feature in
humans is atherosclerosis, which is characterized by
chronic progressive degeneration of arteries with vascular
wall remodeling by connective tissue proliferation, intra-
and extracellular deposits of cholesterol, fatty acids, and
lime, as well as accumulation of collagen and proteo-
glycans. All these lead to increased vascular stiffness and
constriction. Two major hypotheses have been discussed
in the literature in recent decades to explain this process:
‘response to injury’ and ‘lipoprotein-induced athero-
sclerosis’ (108, 109, 110).
The ‘response to injury’ hypothesis is based on the
mechanical damage of the endothelial cell layer due to
trauma, high blood pressure, biochemical damage caused
by bacterial toxins, viral infections, or immune complex
formation and biophysical injury at the molecular level.
Consequently, growth factors and cytokines stimulate
proliferation and migration of smooth muscle cells from
multilayer media into intima; fat deposition leads to
formation of foam cells, fat-laden immune cells of
macrophage type, in the intima and media, which leads
to plaque formation. A modification of this hypothesis is
based on the suspected endothelial dysfunction caused by
a singular injury or by a gradually occurring imbalance of
endothelial function. The ‘lipoprotein-induced athero-
sclerosis’ hypothesis is based on a rapid uptake of
chemically modified LDL by macrophages and subsequent
conversion into foam cells. This hypothesis involves
injury of endothelial cells only as a partial step in a
sequence of complex operations (108, 109, 110).This work is licensed under a Creative Commons
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8–13 3 :R88Based on current knowledge, atherosclerosis does not
occur in horses, but it remains to be evaluated why
arteriosclerosis is not a feature of EMS. It has to be
considered that there is a different amount of HDL and
LDL cholesteryl esters in horses compared with humans.
There is no plasma cholesteryl ester transfer protein in
horses and there is only a small percentage of LDL
cholesteryl esters derived from HDL cholesteryl esters.
However, LDLs are responsible for considering the ‘lipo-
protein-induced atherosclerosis’ hypothesis (111). Horses,
on average, do not reach the age of humans. However,
there are horses, especially ponies, which reach an age of
up to 50 years without any presentation of atherosclerosis.
Another difference is diet: horses are usually strict
vegetarians. Further research is required to answer specific
questions, such as: what prevents the horse from having
this aspect of metabolic syndrome, and could this
mechanism be used as a preventative measure in humans?
Little is known about the pathogenesis of laminitis
and its association with EMS (112). Damage to the lamellar
(dermo-epidermal) interface in the horse’s hoof can result
in structural changes, such as distal phalanx disorienta-
tion and lameness, both of which are defining features of
laminitis (113, 114). However, the role of inflammation,
as well as the mechanism leading to hypoperfusion and
damage to the endothelium of vessels of lamellar tissue in
hyperinsulinemic laminitis, has not been adequately
defined. The basic principles of endothelial damage may
be partly identical to humans. However, the consequence
of this endothelial damage in the vessels of the hoof seems
to be liable to other mechanisms, because it does not result
in the same structural changes observed in arteriosclerosis
(42, 60, 113, 114, 115).
It has already been mentioned that the mechanism
leading to injury of the endothelium of vessels, or rather
clinical onset of laminitis, is the consequence of a chronic
mild generalized inflammatory reaction with a concomi-
tant increase in oxidative stress. This is characterized by an
increased activity of the NAD(P)H oxidase, which leads to
increased production of reactive oxygen radicals. Further-
more, there is a decreased activity of superoxide dismutase,
glutathione peroxidase, and heme oxygenase 2, which
represent the key enzymes of the antioxidant defense
system. Their impairment can result in damage and
endothelial dysfunction of blood vessels in the hoof (50).
Another hypothesis is based on the increased
coagulatory state in blood vessels of the hoof, due to
increased expression of coagulation factors in the liver,
which can ultimately lead to hypoperfusion through to
ischemia (96, 97).http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0038
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hyperinsulinemia in horses was associated with histo-
pathological evidence of laminitis (116).
Histopathological changes early in disease progression
included a decreased secondary epidermal lamellar (SEL)
width and increased histomorphological evidence of
SEL basal (and suprabasal) cell death. Increased cellular
proliferation in SELs, infiltration of the dermis with small
numbers of leucocytes, and basement membrane (BM)
damage occurred later. Some lesions, such as narrowing of
the SELs, were progressive over time. Cellular pathology
preceded leucocyte infiltration and BM pathology, indi-
cating that the latter changes may be secondary or
downstream events in hyperinsulinemic laminitis (116).
Assumptions have been made that hyperinsulinemia
in EMS is due to the vasoregulatory properties of insulin.
Insulin is able to reduce the synthesis of nitric oxide,
which is an important vasodilator. However, there is no
effect of insulin on the synthesis of MAPK, which induces
vasoconstriction. In combination, the result is a superior
drift to vasoconstriction, which could play an important
role in the pathogenesis of laminitis (114, 115, 116, 117,
118, 119, 120, 121).
Another potential mechanism by which insulin-
induced laminitis develops may be significant in endothelin
receptor (ETR) expression (121, 122). Endothelin 1 (ET1) is
a potent vasoconstrictor produced by vascular endothelial
cells binding to at least two receptors, ETRA (EDNRA) and
ETRB (EDNRB) (123). ETRB is located primarily in the
endothelium, and activation of ETRB removes ET1 from
the circulation, thereby resulting in vasodilation (124, 125).
ETRA is located primarily in vascular smooth muscle, and
activation of ETRA in human patients causes cell growth
and contraction of smooth muscle cells, resulting in hyper-
tension (125). A study by Gauff et al. (122) indicated
that localization and expression of ETRA and ETRB varied
within lamellar tissue of the equine forelimb. The results
of the study suggested that the vasoconstrictive effect of
hyperinsulinemia is caused primarily by activation of ETRA
located in smooth muscle of blood vessels (122).
In addition, insulin-like growth factor 1 (IGF1), a
polypeptide with close structural homology to insulin and
well-known effects in terms of activating cell proliferation
and tissue growth and repair, might be another key in the
pathogenesis of laminitis (126).
Gene expression for IGF1 receptor (IGF1R) and
insulin receptor were decreased by 13- to 32-fold during
a prolonged euglycemic, hyperinsulinemic clamp test
during mid-developmental and acute phases of insulin-
induced laminitis. There was no increase in serum IGF1This work is licensed under a Creative Commons
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linemic clamp, consistent with downregulation of both
receptors by insulin. Stimulation of IGF1R by insulin may
lead to inappropriate lamellar epidermal cell proliferation
and lamellar weakening, a potential mechanism for
hyperinsulinemic laminitis. Targeting this receptor may
provide insights into the pathogenesis or identify a novel
therapy for hyperinsulinemic laminitis (127, 128).
The development of laminitis may also follow an
increased activity of TLR4, as part of the generalized
chronic low-grade inflammatory reaction, which is associ-
ated with downregulation of insulin response via SOCS3
and is responsible for increased expression and secretion of
proinflammatory cytokines. Both pathways lead indirectly
to insulin resistance and damage of endothelial cells. TLR4
is gaining increasing attention and its activity may serve as
an early marker of insulin resistance in the horse (71, 129).
Another indicator of chronic inflammation in the vascular
bed of the hoof is increased expression of TNFa, which
also promotes insulin resistance. An increase in this
inflammatory marker could be assessed in ponies with
hyperinsulinemia and previous laminitis (58).
As is commonly known, metalloproteinases play an
important role in weakening lamellar tissue during
laminitis. Therefore, it is of interest if there is an increased
activity of these metalloproteinases in lamellar tissue in
horses suffering from hyperinsulinemia.
It seems most likely that the pathogenesis of laminitis
in EMS is based on multiple factors. At present, no definite
evidence exists as to what extent proinflammatory
conditions, coagulative changes, and disruption of insulin
pathways are involved in the development of the disease.Summary
Metabolic syndrome in humans differs in several aspects
from the equine disease. The most important pathological
factor in humans is affection of the cardiovascular system,
and in horses, the development of laminitis. The
mechanisms that lead to these potentially life-limiting
consequences are not fully comparable, although the
changes in both species take place in the vascular system.
However, inflammatory conditions in adipose tissue and
effects on metabolic and biochemical processes show
similarities between both species.Declaration of interest
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